Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis

scientific article published on 26 October 2012

Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1076029612463424
P698PubMed publication ID23104956

P50authorMichał MyśliwiecQ29078929
Beata NaumnikQ57541897
Ewa Koc-ZorawskaQ117216958
P2093author name stringKatarzyna Klejna
P2860cites workOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationQ24311588
Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityQ24313918
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationQ24603266
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerinQ28295204
Low-molecular-weight heparin for routine hemodialysisQ33381414
Osteoprotegerin ligand: a regulator of immune responses and bone physiology.Q34079327
Osteoprotegerin and bone mineral metabolism in renal failureQ35806269
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.Q35848843
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesisQ36368706
The osteoprotegerin/RANK/RANKL system: a bone key to vascular diseaseQ36686037
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.Q37188485
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerinQ39116155
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase responseQ43654531
PTH differentially regulates expression of RANKL and OPG.Q43832667
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patientsQ43904863
Increased levels of osteoprotegerin in hemodialysis patientsQ44245391
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutritionQ44745296
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulationQ47254973
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patientsQ47422222
Osteoprotegerin and bone mineral density in hemodialysis patients.Q50780000
sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.Q51728628
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.Q53442889
P433issue4
P407language of work or nameEnglishQ1860
P304page(s)433-441
P577publication date2012-10-26
P1433published inClinical and Applied Thrombosis-HemostasisQ5133805
P1476titleEffect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis
P478volume20

Reverse relations

cites work (P2860)
Q97530990Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study
Q58129712Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants
Q33442494Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.
Q38775640Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity

Search more.